TD Cowen Reiterates Buy Rating on Travere Therapeutics (TVTX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Travere Therapeutics (TVTX) PT Raised to $18 at Barclays
September 30, 2024 6:13 AM EDTBarclays analyst Carter Gould raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $18.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "Forthcoming FSGS updates should provide steady set of catalysts de-risking regulatory path (adding $300mn+ to U.S. peak sales potential, and... More
